MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    The Freezing of Gait Change of Direction (FOG-COD) Test: A Novel Measure to Predict Falls

    R. Hand, H. Smith (Philadelphia, USA)

    Objective: To examine the relationship between freezing of gait (FOG), falls history, and a novel clinical measure in persons with parkinsonism. Background: Freezing of gait…
  • 2024 International Congress

    Minimally Clinical Important Differences of Hemifacial Spasm Score-30 (HFS-30) and Hemifacial Spasm Score-7 (HFS-7) for Patients with Hemifacial spasm

    N. Inthapong, W. Saengphatrachai, Y. Pitakpatapee, N. Rattanathamsakul, P. Sirvanitchapoom (Bangkok, Thailand)

    Objective: We aimed to estimate the MCIDs of HFS-30 and HFS-7, and factors associated with the MCID along with baseline and change score of HFS-30…
  • 2024 International Congress

    Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study

    T. Gurevich, S. O'Sullivan, J. Parra, M. O'Meara, J. Zamudio, A. Fasano (Tel Aviv-Yafo, Israel)

    Objective: To assess nighttime use of add-on medications for Parkinson’s disease (PD) in a post hoc analysis of the COSMOS (COmedication Study assessing Mono- and…
  • 2024 International Congress

    Improvement in Upright Stability subscale of mFARS with Vatiquinone Treatment in MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial

    D. Lynch, A. Duquette, M. França Jr, S. Perlman, A. Durr, E. Bertini, A. Darling, K. Mathews, L. Schöls, A. Fournier, M. Delatycki, S. Subramony, R. Roxburgh, O. Zhang, C. Rummey, A. Salvucci, B. Yao, J. Cherry, L. Golden, T. Zesiewicz (Philadelphia, USA)

    Objective: Describe the results of vatiquinone on the Upright Stability Subscale (USS) from MOVE-FA (NCT04577352), the 72-week placebo-controlled phase 3 study of patients with Friedreich…
  • 2024 International Congress

    Palliative and end-of-life care in Parkinson’s disease : French patients’ perceptions and knowledge

    M. Auffret, L. Cronier, G. Robert, M. Béreau, M. Giffard, M. Vérin (Rennes, France)

    Objective: (1) Assess patients' perceptions and knowledge of palliative and end-of-life care in PD; (2) evaluate (i) whether patients discuss these topics with healthcare professionals and/or…
  • 2024 International Congress

    Assessing Barriers to Advance Care Planning in Parkinson’s Disease Within a Cuban-American Population

    T. Peabody, M. Abou-Ezzi, L. Hernandez, H. Moore, S. Vargas-Parra, A. Cruz, D. Shpiner (Miami, USA)

    Objective: Determine attitudes toward advance care planning among Cuban-American people with Parkinson’s disease (PWP). Background: Advance care planning (ACP) is a process that allows individuals…
  • 2024 International Congress

    The Impact of Apathy and Impulsivity on Caregivers in Atypical Parkinsonian Syndromes

    M. Manconi, J. Donnelly, L. Massey, K. Tluchowska, S. Anugu, J. Rowe, B. Ghosh (Southampton, United Kingdom)

    Objective: This study aims to investigate the impact of apathy and impulsivity on the quality of life and burden for carergivers of people with Atypical…
  • 2024 International Congress

    Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study

    S. Markova, M. Baladi, M. Lee, C. Chen (Palo Alto, USA)

    Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…
  • 2024 International Congress

    A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.

    P. Millar Vernetti, D. Mirski, JC. Dodart, A. Wood, HJ. Yu, J. Boyd, P. Kundu, R. Setton, D. Silbersweig, E. Stern, C. Lucero, S. Gerrol, H. Kaufmann, J. Martinez (New York, USA)

    Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…
  • 2024 International Congress

    Clinical and Neurophysiological Response of Different Protocols of Non-Invasive Spinal Neuromodulation in Anti-Gad Positive Stiff Person Syndrome: A Case Report

    V. Maciel, G. Silva, R. Carra, J. Baima, J. Oliveira, M. Silva, P. Lacerda, K. Massruha, C. Heise, C. Tanaka, R. Cury (São Paulo, Brazil)

    Objective: To evaluate the effects of non-invasive neuromodulation techniques transpinal magnetic stimulation (TsMS) and transcutaneous electrical stimulation (TENS) in Stiff person syndrome (SPS). Background: SPS…
  • « Previous Page
  • 1
  • …
  • 128
  • 129
  • 130
  • 131
  • 132
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • An atypical and interesting feature of Parkinson´s disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley